Core Insights - Arima Genomics has completed a $22 million Series C funding round led by Illumina Ventures, aimed at launching a "Focused Pipeline Of Clinical Assays" to utilize sequencing methods for identifying 3D genomic structures such as gene fusions and rearrangements [1][2] - The trend indicates that 3D Genomics is becoming a new focal point at the intersection of basic research and precision medicine, following advancements in spatial transcriptomics and single-cell sequencing [2][12] - Arima's transition from a research tool developer to a clinical testing platform is driven by the realization that traditional linear sequencing methods may miss pathogenic variations hidden in 3D structures, which are crucial for precision treatment [3][12] Funding and Development Timeline - 2015: Arima Genomics was founded, initially focusing on developing high-throughput Hi-C technology [5] - 2022: Completed a $7 million Series B funding round to expand product offerings and bioinformatics platform [4][5] - 2023: Joined the BRAIN Initiative and established Aventa Genomics in collaboration with Protean BioDiagnostics, entering the clinical testing space [4][5] - 2025: Completed a $22 million Series C funding round, with a leadership change appointing Tom Willis as CEO [1][5] Product and Service Offerings - Arima's product suite includes standardized kits and modular analysis processes, such as the Arima-HiC+ kit, which simplifies complex Hi-C experiments for reproducible results [7][11] - The company offers clinical services through its CLIA-certified Aventa laboratory, focusing on structural variant detection in clinical samples, particularly for cancer diagnostics [9][12] - Arima provides a comprehensive "turnkey" outsourcing service for institutions lacking experimental capabilities, covering all steps from library preparation to data analysis [10][12] Applications and Market Position - The 3D Genomics technology represented by Arima is expanding into high-value applications such as tumor diagnostics, gene editing safety assessments, and viral integration detection [12][13] - Arima's platform is increasingly recognized as a bridge between gene regulation mechanisms and disease variation research, enhancing its relevance in precision medicine [12][13] - The company’s approach to modularization and focus on clinically relevant applications serves as a model for other enterprises in the 3D genomics field, particularly in China [16]
融资2200万美元，Arima Genomics如何推动三维基因组产业落地？
3 6 Ke·2025-08-11 01:42